733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins

由 Borroto-Esoda, Katyna, Angulo, David A, Azie, Nkechi
發表在 Open Forum Infect Dis (2020)

The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience

由 Haider, Shariq, Rotstein, Coleman, Horn, David, Laverdiere, Michel, Azie, Nkechi
出版 2014

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis

由 Sobel, Jack D., Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David
發表在 Antimicrob Agents Chemother (2021)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

由 Borroto-Esoda, Katyna, Azie, Nkechi, Ashbaugh, Alan, Cushion, Melanie, Angulo, David A
發表在 Open Forum Infect Dis (2020)

Intravenous diltiazem and CYP3A-mediated metabolism

由 Masica, Andrew L, Azie, Nkechi E, Brater, D Craig, Hall, Stephen D, Jones, David R
出版 2000

Safety and Pharmacokinetic Profiles of Repeated-Dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis

由 Benjamin, Daniel K., Deville, Jaime G., Azie, Nkechi, Kovanda, Laura, Roy, Mike, Wu, Chunzhang, Arrieta, Antonio
出版 2013

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, o...

由 Marukutira, Tafireyi, Huprikar, Shirish, Azie, Nkechi, Quan, Shun-Ping, Meier-Kriesche, Herwig-Ulf, Horn, David L
出版 2014

202 Antifungal Stewardship: The Clinician's Perspective on Barriers to Implementation

由 Safdar, Amar, Goff, Debra, Gallagher, Jason, Hsu, Donald, Eiland, Edward, Hanrahan, Jennifer, Smith, Purvi, Azie, Nkechi
發表在 Open Forum Infect Dis (2014)

Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis

由 Gebremariam, Teclegiorgis, Wiederhold, Nathan P., Alqarihi, Abdullah, Uppuluri, Priya, Azie, Nkechi, Edwards, John E., Ibrahim, Ashraf S.
發表在 J Antimicrob Chemother (2017)

Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents

由 Hope, William W., Kaibara, Atsunori, Roy, Michael, Arrieta, Antonio, Azie, Nkechi, Kovanda, Laura L., Benjamin, Daniel K.
發表在 Antimicrob Agents Chemother (2015)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis

由 Harrington, Rachel, Lee, Edward, Yang, Hongbo, Wei, Jin, Messali, Andrew, Azie, Nkechi, Wu, Eric Q., Spalding, James
發表在 Adv Ther (2016)

A Risk Score for Fluconazole Failure among Patients with Candidemia

由 Ostrosky-Zeichner, Luis, Harrington, Rachel, Azie, Nkechi, Yang, Hongbo, Li, Nanxin, Zhao, Jing, Koo, Valerie, Wu, Eric Q.
發表在 Antimicrob Agents Chemother (2017)

Comparing Methods of Measurement for Detecting Drug‐Induced Changes in the QT Interval: Implications for Thoroughly Conducted ECG Studies

由 Azie, Nkechi E., Adams, Gregory, Darpo, Borje, Francom, Steven F., Polasek, Emery C., Wisser, Joy M., Fleishaker, Joseph C.
發表在 Ann Noninvasive Electrocardiol (2004)

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans

由 Fleishaker, Joseph C, Ryan, Kristi K, Jansat, Josep M, Carel, Barabara J, Bell, David J A, Burke, Moira T, Azie, Nkechi E
出版 2001

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

由 Pfaller, Michael A., Andes, David R., Diekema, Daniel J., Horn, David L., Reboli, Annette C., Rotstein, Coleman, Franks, Billy, Azie, Nkechi E.
出版 2014

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study

由 Kontoyiannis, Dimitrios P., Yang, Hongbo, Song, Jinlin, Kelkar, Sneha S., Yang, Xi, Azie, Nkechi, Harrington, Rachel, Fan, Alan, Lee, Edward, Spalding, James R.
發表在 BMC Infect Dis (2016)

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

由 Andes, David, Azie, Nkechi, Yang, Hongbo, Harrington, Rachel, Kelley, Caroline, Tan, Ruo-Ding, Wu, Eric Q., Franks, Billy, Kristy, Rita, Lee, Edward, Khandelwal, Nikhil, Spalding, James
發表在 Antimicrob Agents Chemother (2016)

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental In...

由 Petraitis, Vidmantas, Petraitiene, Ruta, Katragkou, Aspasia, Maung, Bo Bo Win, Naing, Ethan, Kavaliauskas, Povilas, Barat, Stephen, Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
發表在 Antimicrob Agents Chemother (2020)

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections

由 Ghannoum, Mahmoud, Arendrup, Maiken Cavling, Chaturvedi, Vishnu P., Lockhart, Shawn R., McCormick, Thomas S., Chaturvedi, Sudha, Berkow, Elizabeth L., Juneja, Deven, Tarai, Bansidhar, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
發表在 Antibiotics (Basel) (2020)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses

由 Thompson, George R., Rendon, Adrian, Ribeiro dos Santos, Rodrigo, Queiroz-Telles, Flavio, Ostrosky-Zeichner, Luis, Azie, Nkechi, Maher, Rochelle, Lee, Misun, Kovanda, Laura, Engelhardt, Marc, Vazquez, Jose A., Cornely, Oliver A., Perfect, John R.
發表在 Clin Infect Dis (2016)